G6PD and Plasmodium vivax malaria: Given the paucity of hypnozoitocidal candidates and narrow safety profiles with TQ, the radical cure activity of T111 is promising, whether on its own or as a synergistic partner to improve the TQ therapeutic window for treatment and prevention of vivax malaria, including in G6PD deficient patients.